MAPRECOS

Maprecos is a French biotechnology company based at the Genopole biocluster, dedicated to developing first-in-class therapies for rare genetic mineralization disorders. The company's primary focus is on Pseudoxanthoma Elasticum (PXE) and General Arterial Calcification of Infancy (GACI), which are characterized by the progressive and debilitating calcification of soft tissues. Maprecos leverages a deep understanding of the metabolic pathways involving inorganic pyrophosphate (PPi) to develop small molecule inhibitors of Tissue-Nonspecific Alkaline Phosphatase (TNAP). By preventing the degradation of PPi, these candidates aim to halt or reverse ectopic calcification in the skin, eyes, and cardiovascular system. The company was founded by experts in the field and has received recognition through the French i-Lab innovation competition.